Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -186.26M | -178.23M | -175.72M | -190.05M | -160.93M |
| Total Depreciation and Amortization | 18.96M | 19.03M | 19.17M | 18.91M | 18.28M |
| Total Amortization of Deferred Charges | -- | 0.00 | 0.00 | 0.00 | 7.20M |
| Total Other Non-Cash Items | 46.38M | 31.72M | 26.18M | 26.74M | -16.00M |
| Change in Net Operating Assets | -1.96M | -4.24M | -10.19M | 7.64M | 19.18M |
| Cash from Operations | -122.87M | -131.71M | -140.57M | -136.75M | -132.26M |
| Capital Expenditure | -730.00K | -813.00K | -883.00K | -3.03M | -6.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.95M | 35.57M | 34.98M | 123.67M | 118.82M |
| Cash from Investing | 12.22M | 34.76M | 34.10M | 120.64M | 112.67M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 75.49M | 75.49M | 75.49M | 75.55M | 265.00K |
| Repurchase of Common Stock | -666.00K | -846.00K | -846.00K | -180.00K | -180.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 25.07M | 21.94M | 21.94M | 20.00M | -- |
| Cash from Financing | 99.89M | 96.58M | 96.58M | 95.37M | 85.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.76M | -375.00K | -9.89M | 79.25M | -19.51M |
